Supreme Court Blocks 5th Circuit Ruling on Abortion Pill Access 
Should I take zinc or eat oysters to ward off colds, boost my immune system or improve fertility? 
CDC Monitors U.S. Travelers After Hantavirus Outbreak on Luxury Cruise Ship 
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO 
Genesis Minerals to Acquire Vault in A$5.6 Billion Deal After Regis Withdraws 
RFK Jr. Spokesman Resigns Over Trump Administration’s Flavored E-Cigarette Policy 
US Plans Kenya Ebola Quarantine Facility Amid Congo Outbreak 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth 
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results 
The government is ‘doubling down’ on its social media ban. But bigger penalties for platforms aren’t enough 
Yaskawa Electric Shares Slide as Weak Profit Overshadows Strong AI Demand 
Deutsche Bank Fined A$2 Million by ASIC Over OTC Derivatives Reporting Errors 
NIH Infectious Disease Leadership Shake-Up Raises Concerns Amid Ebola, Hantavirus Outbreaks 
Stellantis Q2 Vehicle Shipments Rise 10% as North America Drives Growth 
AstraZeneca (NASDAQ: AZN) has unveiled plans to invest $50 billion in U.S. manufacturing and R&D infrastructure by 2030, marking one of the largest expansions in the pharmaceutical industry. The move responds to renewed pressure from President Donald Trump’s administration to localize drug production and reduce reliance on imports.
The Anglo-Swedish drugmaker will build a new manufacturing plant in Virginia focused on active ingredients for weight-loss drugs, including a GLP-1 candidate and an oral PCSK9 inhibitor. It also plans to expand operations in Maryland, Massachusetts, California, Indiana, and Texas, enhancing its R&D capabilities and clinical trial supply chain.
CEO Pascal Soriot announced the investment in Washington, citing the need for global pricing reform. “The U.S. cannot shoulder the world’s R&D costs alone,” he said, calling for other nations to pay more for drugs.
Over 40% of AstraZeneca’s 2024 revenue came from the U.S., the world’s largest pharmaceutical market valued at $635 billion. The company aims to hit $80 billion in annual revenue by 2030, with half coming from the U.S.
The $50 billion pledge follows Trump’s threats of pharmaceutical tariffs, with a possible grace period of 12–18 months. U.S. Commerce Secretary Howard Lutnick emphasized the administration’s goal to end foreign dependency in the drug supply chain.
The investment is in addition to a $3.5 billion commitment made in November 2024. It mirrors a similar $50 billion pledge by Roche and aligns with major expansion plans from Eli Lilly, Johnson & Johnson, Novartis, and Sanofi.
AstraZeneca employs about 18,000 people in the U.S. and hinted at creating tens of thousands of new jobs, though exact figures were not disclosed. The company declined to comment on rumors of a potential U.S. stock market listing shift.
